piperacillin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 2187 61477-96-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • piperacillin hydrate
  • piperacillin
  • piperacillin sodium
  • pipracil
  • piperacillin sodium salt
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
  • Molecular weight: 517.56
  • Formula: C23H27N5O7S
  • CLOGP: 1.36
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 3
  • TPSA: 156.43
  • ALOGS: -3.64
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
14 g P
14 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 714.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 71 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 772.85 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.96 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 324.84 49.12 113 1400 28009 2328563
Pyrexia 300.13 49.12 127 1386 53581 2302991
Drug reaction with eosinophilia and systemic symptoms 244.99 49.12 63 1450 5455 2351117
Toxic epidermal necrolysis 242.40 49.12 56 1457 3088 2353484
Rash 227.04 49.12 108 1405 59450 2297122
Rash maculo-papular 215.54 49.12 54 1459 4198 2352374
Tubulointerstitial nephritis 154.03 49.12 37 1476 2401 2354171
Pancytopenia 150.71 49.12 51 1462 11401 2345171
Thrombocytopenia 146.18 49.12 57 1456 19074 2337498
Drug hypersensitivity 139.54 49.12 72 1441 46571 2310001
Clostridium difficile infection 132.90 49.12 34 1479 2856 2353716
Stevens-Johnson syndrome 128.95 49.12 36 1477 4223 2352349
Septic shock 123.38 49.12 39 1474 7015 2349557
Renal tubular necrosis 110.07 49.12 26 1487 1564 2355008
Hypotension 108.23 49.12 54 1459 32382 2324190
Clostridium difficile colitis 108.13 49.12 27 1486 2052 2354520
Eosinophilia 107.95 49.12 29 1484 2941 2353631
Pruritus 107.14 49.12 59 1454 43281 2313291
Anaphylactic reaction 99.77 49.12 36 1477 9669 2346903
Acute respiratory distress syndrome 91.30 49.12 26 1487 3266 2353306
Multiple organ dysfunction syndrome 88.57 49.12 31 1482 7610 2348962
Erythema 84.13 49.12 42 1471 25117 2331455
Neutropenia 81.08 49.12 39 1474 21509 2335063
Diarrhoea 80.42 49.12 63 1450 83501 2273071
Dyspnoea 79.31 49.12 61 1452 78672 2277900
Blood creatinine increased 78.88 49.12 31 1482 10502 2346070
Hepatocellular injury 77.42 49.12 24 1489 4031 2352541
Platelet count decreased 76.24 49.12 34 1479 15779 2340793
Drug ineffective 75.66 49.12 66 1447 101558 2255014
Cholestasis 75.17 49.12 23 1490 3698 2352874
Cardiac arrest 74.86 49.12 33 1480 14897 2341675
Renal impairment 73.10 49.12 29 1484 10063 2346509
Hepatic function abnormal 71.66 49.12 25 1488 6067 2350505
Febrile neutropenia 70.98 49.12 29 1484 10853 2345719
Acute generalised exanthematous pustulosis 68.83 49.12 18 1495 1640 2354932
Respiratory failure 64.90 49.12 29 1484 13499 2343073
Nephropathy toxic 64.60 49.12 16 1497 1172 2355400
Chills 64.11 49.12 30 1483 15522 2341050
Pneumonia 62.59 49.12 44 1469 49252 2307320
Renal failure 60.99 49.12 30 1483 17319 2339253
Disseminated intravascular coagulation 60.46 49.12 19 1494 3331 2353241
Leukopenia 59.15 49.12 25 1488 10171 2346401
Condition aggravated 58.76 49.12 36 1477 31943 2324629
Interstitial lung disease 58.47 49.12 23 1490 7789 2348783
Haemophagocytic lymphohistiocytosis 57.33 49.12 15 1498 1368 2355204
Drug eruption 56.81 49.12 18 1495 3241 2353331
Sepsis 56.27 49.12 29 1484 18459 2338113
Clostridial infection 54.83 49.12 13 1500 791 2355781
Encephalopathy 54.71 49.12 19 1494 4542 2352030
Pseudomembranous colitis 54.10 49.12 12 1501 542 2356030
Linear IgA disease 53.55 49.12 11 1502 343 2356229
Cardiac failure 51.90 49.12 24 1489 12070 2344502
Agranulocytosis 51.58 49.12 17 1496 3465 2353107
Leukocytosis 51.14 49.12 17 1496 3559 2353013
Rash erythematous 49.70 49.12 19 1494 5957 2350615

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 548.84 51.04 224 2060 34720 1709777
Pyrexia 421.88 51.04 203 2081 46197 1698300
Rash 390.03 51.04 182 2102 38511 1705986
Thrombocytopenia 358.09 51.04 144 2140 21105 1723392
Drug reaction with eosinophilia and systemic symptoms 343.47 51.04 98 2186 4972 1739525
Tubulointerstitial nephritis 292.21 51.04 77 2207 2881 1741616
Toxic epidermal necrolysis 221.03 51.04 59 2225 2312 1742185
Eosinophilia 210.99 51.04 62 2222 3465 1741032
Agranulocytosis 188.40 51.04 57 2227 3519 1740978
Neutropenia 176.52 51.04 84 2200 18176 1726321
Condition aggravated 164.79 51.04 84 2200 21066 1723431
Renal tubular necrosis 152.26 51.04 43 2241 2076 1742421
Drug ineffective 151.47 51.04 119 2165 63682 1680815
Sepsis 144.95 51.04 75 2209 19363 1725134
Rash maculo-papular 140.64 51.04 46 2238 3657 1740840
Pathogen resistance 129.89 51.04 33 2251 1056 1743441
Clostridium difficile colitis 126.38 51.04 35 2249 1569 1742928
Diarrhoea 124.40 51.04 99 2185 53753 1690744
Septic shock 122.14 51.04 51 2233 8058 1736439
Multiple organ dysfunction syndrome 118.96 51.04 52 2232 9190 1735307
Drug resistance 118.10 51.04 39 2245 3191 1741306
Hepatic function abnormal 115.01 51.04 47 2237 7027 1737470
Stevens-Johnson syndrome 112.65 51.04 38 2246 3319 1741178
Clostridium difficile infection 109.38 51.04 32 2252 1749 1742748
Drug hypersensitivity 108.66 51.04 57 2227 15078 1729419
Blood creatinine increased 107.22 51.04 55 2229 13891 1730606
Nephropathy toxic 105.84 51.04 31 2253 1701 1742796
Alanine aminotransferase increased 104.85 51.04 52 2232 12226 1732271
Renal failure 104.24 51.04 61 2223 19956 1724541
Clostridial infection 102.12 51.04 25 2259 684 1743813
Respiratory failure 99.48 51.04 53 2231 14452 1730045
Aspartate aminotransferase increased 99.13 51.04 48 2236 10708 1733789
Renal impairment 95.88 51.04 49 2235 12265 1732232
Rash erythematous 95.22 51.04 35 2249 3930 1740567
Cholestasis 83.02 51.04 31 2253 3634 1740863
Pancytopenia 82.07 51.04 43 2241 11314 1733183
Anaphylactic reaction 80.54 51.04 35 2249 6078 1738419
Acute respiratory distress syndrome 76.66 51.04 29 2255 3522 1740975
Chills 75.29 51.04 41 2243 11646 1732851
Toxic skin eruption 69.83 51.04 23 2261 1860 1742637
Leukopenia 69.60 51.04 35 2249 8445 1736052
Drug eruption 67.17 51.04 25 2259 2901 1741596
Staphylococcal infection 65.42 51.04 28 2256 4679 1739818
Pruritus 64.89 51.04 48 2236 23174 1721323
Pseudomembranous colitis 63.13 51.04 16 2268 505 1743992
Bronchopulmonary aspergillosis 61.58 51.04 20 2264 1546 1742951
Urticaria 55.01 51.04 34 2250 12207 1732290
Drug-induced liver injury 54.20 51.04 22 2262 3215 1741282
Blister 52.46 51.04 23 2261 4069 1740428
Leukocytosis 52.34 51.04 22 2262 3511 1740986
Disseminated intravascular coagulation 51.86 51.04 22 2262 3592 1740905
Hepatitis 51.32 51.04 24 2260 4931 1739566

Pharmacologic Action:

SourceCodeDescription
ATC J01CA12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Penicillins with extended spectrum
ATC J01CR05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Combinations of penicillins, incl. beta-lactamase inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Infection due to Pseudomonas aeruginosa indication 11218009
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Postoperative infection indication 33910007
Pneumonia due to Pseudomonas indication 41381004
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Appendicitis indication 74400008 DOID:8337
Abdominal abscess indication 75100008
Septicemia due to Bacteroides indication 79587009
Septicemia due to Serratia indication 82091000
Infection of bone indication 111253001
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Proteus septicemia indication 300986008
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Septicemia due to enterococcus indication 310669007
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Nosocomial pneumonia indication 425464007
Sepsis due to Pseudomonas indication 448813005
Sepsis due to Gram negative bacteria indication 449082003
Urinary tract infection caused by Klebsiella indication 369001000119100
Skin and Skin Structure Bacteroides Fragilis Infection indication
E. Coli Appendicitis indication
Bacteroides Pneumonia indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Bacteroides Peritonitis indication
Skin and Skin Structure Enterococcus Infection indication
Prevention of Perioperative Infection indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Bacteroides Pelvic Inflammatory Disease indication
Bacteroides Pelvic Cellulitis indication
Bacteroides Endometritis indication
E. Coli Peritonitis indication
Pseudomonas Aeruginosa Joint Infection indication
Bacteroides Complicated Appendicitis indication
Enterococcus Urinary Tract Infection indication
E. Coli Pelvic Inflammatory Disease indication
Skin and Skin Structure Serratia Infection indication
Bacteroides Appendicitis indication
Enterobacter Pneumonia indication
Enterococcus Peritonitis indication
Cesarean Section Infection Prevention indication
Vaginal Hysterectomy Infection Prevention indication
Enterococcus Pelvic Inflammatory Disease indication
Bacteroides Osteomyelitis indication
Infection Prevention for GI Surgery indication
Enterococcus Joint Infection indication
Clostridium Peritonitis indication
Complicated Skin and Skin Structure Infection indication
Inflammatory Disease of Female Pelvic Organs indication
Pseudomonas Aeruginosa Osteomyelitis indication
Peptostreptococcus Pelvic Inflammatory Disease indication
Complicated Proteus UTI indication
Staphylococcus Nosocomial Pneumonia indication
Skin and Skin Structure Acinetobacter Infection indication
Bacteroides Joint Infection indication
Enterococcus Complicated UTI indication
Skin and Skin Structure Proteus Infection indication
Neisseria Gonorrhea Pelvic Cellulitis indication
E. Coli Complicated Appendicitis indication
E. Coli Endometritis indication
Diabetic Foot Infection indication
Enterococcus Osteomyelitis indication
Enterococcus Endometritis indication
Complicated UTI with Pseudomonas Aeruginosa indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Enterococcus Pelvic Cellulitis indication
Ecthyma gangrenosum off-label use 17732003
Sepsis of the newborn off-label use 206376005
Diverticulitis of gastrointestinal tract off-label use 271366000
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic
pKa2 12.64 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 2GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 2GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK
Streptokinase A Enzyme EC50 6.55 WOMBAT-PK
Beta-lactamase Enzyme Ki 6.70 CHEMBL

External reference:

IDSource
4019896 VUID
N0000147981 NUI
C0031955 UMLSCUI
D00466 KEGG_DRUG
74575000 SNOMEDCT_US
4019896 VANDF
8339 RXNORM
372836004 SNOMEDCT_US
d00057 MMSL
004832 NDDF
CHEMBL702 ChEMBL_ID
DB00319 DRUGBANK_ID
CHEMBL1200820 ChEMBL_ID
M98T69Q7HP UNII
59703-84-3 SECONDARY_CAS_RN
WPP PDB_CHEM_ID
CHEBI:8232 CHEBI
D010878 MESH_DESCRIPTOR_UI
43672 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-2409 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 13 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-2411 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 13 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-2413 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 13 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-2416 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 36 g INTRAVENOUS NDA 13 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-5501 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 36 g INTRAVENOUS NDA 13 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-8852 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS NDA 18 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-8854 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS NDA 18 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-8855 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS NDA 18 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-8859 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 36 g INTRAVENOUS NDA 18 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 18 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 18 sections
Zosyn HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 18 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 12 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3113 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3114 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9213 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9214 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 17 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-012 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 18 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-679 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 36 g INTRAVENOUS ANDA 18 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-164 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 17 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-165 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 17 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-166 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 17 sections